Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
55.2 PLN | -0.54% | -3.83% | -4.00% |
Sales 2024 * | 152M 38.08M | Sales 2025 * | 218M 54.55M | Capitalization | 1.28B 320M |
---|---|---|---|---|---|
Net income 2024 * | -124M -31.1M | Net income 2025 * | -119M -29.84M | EV / Sales 2024 * | 7.92 x |
Net cash position 2024 * | 73.62M 18.46M | Net Debt 2025 * | 18.41M 4.62M | EV / Sales 2025 * | 5.95 x |
P/E ratio 2024 * |
-13.8
x | P/E ratio 2025 * |
-12.3
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 70.54% |
Latest transcript on Ryvu Therapeutics S.A.
1 day | -0.54% | ||
1 week | -3.83% | ||
Current month | -7.07% | ||
1 month | -7.85% | ||
3 months | -7.69% | ||
6 months | -12.10% | ||
Current year | -4.00% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 06-12-31 | |
Hendrik Nogai
CTO | Chief Tech/Sci/R&D Officer | - | 22-01-31 |
Chief Operating Officer | 38 | 12-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 72 | - | |
Scott Fields
BRD | Director/Board Member | 69 | - |
Thomas Turalski
BRD | Director/Board Member | - | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 55.2 | -0.54% | 4,408 |
24-03-27 | 55.5 | -1.25% | 4,299 |
24-03-26 | 56.2 | -1.06% | 2,501 |
24-03-25 | 56.8 | -0.53% | 1,010 |
24-03-22 | 57.1 | -0.35% | 1,046 |
Delayed Quote Warsaw S.E., March 28, 2024 at 12:55 pm EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-4.00% | 322M | |
+2.73% | 108B | |
+9.59% | 104B | |
+6.58% | 23.66B | |
-12.59% | 22.1B | |
-3.29% | 19.71B | |
-35.36% | 18.2B | |
-13.29% | 16.19B | |
+4.68% | 13.72B | |
+34.25% | 12.22B |